Effect of Bu Yang Huan Wu Decoction on ischemia reperfusion injury after limb replantation in rats

doi:10.3969/j.issn.2095-4344.2014.36.016

Abstract

Abstract:

BACKGROUND: Traditional Chinese medicine plays a specific role in the clinical diagnosis and treatment of ischemia reperfusion injury.
OBJECTIVE: To investigate the effect of Bu Yang Huan Wu Decoction on ischemia reperfusion injury in rats after replantation of of lower limbs, and evaluate the protective effect and mechanism of ischemic tissue.
METHODS: A total of 120 Wistar rats were randomly divided into four groups: normal control (intragastric administration of saline after anesthesia), Bu Yang Huan Wu Decoction (intragastric administration of 10 mL/kg Bu Yang Huan Wu Decoction immediately after reperfusion), edaravone (intravenous administration of 10 mL/kg edaravone immediately after reperfusion), and blank control (intragastric administration of saline) groups. At 24 hours after reperfusion, the myeloperoxidase, lactate dehydrogenase, nitricoxide synthase, inducible nitricoxide synthase, constitutive nitricoxide synthase level in the blood were detected. At 1 week after reperfusion, the activity of superoxide dismutase in gastrocnemius tissue, nitrogen monoxidum and malondialdehyde, and the load of Ca²⁺ were assayed. RT-PCR semiquantitative analysis was performed to detect bcl-2 mRNA and bax mRNA transcriptional levels in the gastrocnemius.
RESULTS AND CONCLUSION: Bu Yang Huan Wu Decoction protected the rats from ischemia reperfusion injury by reducing the production of oxygen free radicals, reinforcing the activity of superoxide dismutase, lessening the calcium overload, decreasing the production of nitrogen monoxidum, up-regulating the expression of anti-apoptotic gene bcl-2, down-regulating the expression of pro-apoptotic gene bax, and attenuating the injury of skeletal muscle after ischemia reperfusion injury. Bu Yang Huan Wu Decoction has significant protection on cerebral ischemia reperfusion injury in rats after replantation of severed limb, which may be related to the scavenge of free radicals, inhibition of skeletal cells apoptosis, and attenuation of reperfusion injury.

中国组织工程研究杂志出版内容重点：肾移植；肝移植；移植；心脏移植；组织移植；皮肤移植；皮瓣移植；血管移植；器官移植；组织工程

全文链接：

Key words: drugs, Chinese herbal, reperfusion injury, muscle, skeletal

CLC Number:

R318

Zhang Hui, Yuan Zhi-guo, Shao Jian-jun. Effect of Bu Yang Huan Wu Decoction on ischemia reperfusion injury after limb replantation in rats[J]. Chinese Journal of Tissue Engineering Research, 2014, 18(36): 5830-5835.

Figures/Tables 3

2.1 实验动物数量分析 120只Wistar大鼠均进入结果分析。 2.2 各组动物肢体成活情况检测再灌注1周后，观察再植后肢体成活情况。补阳还五汤组20只大鼠，肢体全部成活，成活率100%；空白对照组20只大鼠，术后有6只大鼠逐渐出现肢体坏死，成活14只，成活率70%，提示补阳还五汤组肢体成活率明显增高(P < 0.001)；依达拉奉组成活18只，成活率90%，与补阳还五汤组相比差异有显著性意义(P < 0.05)。 2.3 血管吻合情况吻合口通畅情况：术中见血管搏动良好，通畅实验良好。所有大鼠吻合口即时通畅率100%，各组间差异无显著性意义。血管内膜情况：空白对照组吻合口处有少量血栓形成，依达拉奉组血管吻合口处不平整，欠光滑，有少量纤维组织依附，但血管通畅均不受影响；补阳还五汤组血管内膜均平整光滑，无狭窄或闭锁及血栓形成。 2.4 各组血清指标检测结果再灌注24 h后，与正常对照组比较，补阳还五汤组、依达拉奉组血清中髓过氧化酶、乳酸脱氢酶、总一氧化氮合酶、诱导型一氧化氮合酶活性均增高(P < 0.001)，空白对照组血清中结构型一氧化氮合酶活性降低(P < 0.05)，补阳还五汤组血清中结构型一氧化氮合酶活性增高，差异有显著性意义(P < 0.05)；与空白对照组比较，补阳还五汤组、依达拉奉组血清中髓过氧化酶、乳酸脱氢酶、诱导型一氧化氮合酶活性均降低(P < 0.05)，总一氧化氮合酶、结构型一氧化氮合酶活性增高(P < 0.05)；与依达拉奉组比较，补阳还五汤组髓过氧化酶、乳酸脱氢酶、诱导型一氧化氮合酶活性均降低(P < 0.05)，结构型一氧化氮合酶、总一氧化氮合酶活性差异无显著性意义(表1)。 2.5 各组腓肠肌组织中超氧化物歧化酶、一氧化氮、丙二醛、Ca2+浓度的测定下肢再植后24 h，与空白对照组相比，其余3组腓肠肌组织中超氧化物歧化酶活性、一氧化氮、丙二醛含量均明显降低，钙负载水平显著降低(P < 0.01)；与正常对照组相比，其余3组腓肠肌组织中超氧化物歧化酶活性、一氧化氮、丙二醛含量均显著升高，钙负载水平亦显著升高(P < 0.01)；与依达拉奉组相比，补阳还五汤组能有效降低血清中超氧化物歧化酶、一氧化氮、Ca2+含量(P < 0.05)，丙二醛含量差异无显著性意义(P > 0.05)，见表2。"

References

[1] 任举山,石海英,魏飞.复杂断肢(指)再植的治疗[J].实用手外科杂志,2012,26(4):1671-1672.
[2] 黄慕康,仲嘉,王澍寰.对断肢(指)再植苦干问题的讨论[J].中华显微外科杂志,1994,1(1):48-68.
[3] Connor N ,Williams C,Ciesielski W,et al .Global effects of xanthine oxi dase stress on alveolar type II cells. Pediatr Crit Care Med.2002;3(3): 280-287.
[4] Nanavat y UB,Pawliczak R,Doni ger J, et al.Oxidant induced cell death i n respi- ratory epithelial cells is due to DNA damage and loss of ATP.Exp Lung Res.2002;28 (8):591-607.
[5] Kato R,Foex P.Myocardial protection by anesthetic agent sagainst isch emia-reperfusion injury: an update for anesthesiologists.Can J A naesth.2002; 49(8):777-791 .
[6] 金惠铭.病理生理学[M].5版.北京:人民卫生出版社,2000: 110-117.
[7] 郑曙云,徐建国,赵振中.参附注射液对大鼠心肌缺血再灌注损伤的影响[J].中国中西医结合杂志,2004,24(6):541-544.
[8] 谢明剑.补阳还五汤与低分子肝素钙治疗急性脑梗死临床疗效比较[J].中国中西医结合急救杂志,2007,14(3):189-190.
[9] 陈洁,曾耀英,曾慧兰,等.补阳还五汤预先干预对大鼠脑死亡后心肺炎症细胞因子表达的抑制作用[J].中草药,2010,41(5): 757-761.
[10] 张淑萍,梁燕,邓常青.补阳还五汤及其有效部位对大鼠脑缺血再灌注后casp ase表达的影响[J].中草药,2006,37(7):1041-1045.
[11] 刘柏炎,蔡光先,刘维,等.补阳还五汤对大鼠局灶性脑缺血后血管内皮生长因子及其受体 Flk1 的影响[J].中草药,2007,38(3): 394-397.
[12] 吴兰鸥,詹合琴,闫俊岭,等.三七皂苷 Rg1 对大鼠脑缺血-再灌注损伤的保护作用及机制探讨[J].中草药,2006,37(2):229-233.
[13] 关欣,纪影实,李红,等.蒺藜皂苷对脑缺血再灌注损伤大鼠的保护作用[J].中草药,2006, 37(6):904-906.
[14] 刘向前,邹亲朋,冯胜,等.五加苷对大鼠脑梗死的保护作用[J].药物评价研究,2010,33(2): 95-97.
[15] 何志,仇树林.丹参对皮瓣缺血再灌注损伤的影响及机制[J].中国组织工程研究与临床康复,2010,14(53):10021-10025.
[16] McCord JM.Oxygen-derived free radicals in past ischemic issue injury.N E J Med.1985;312(3):159-162.
[17] Sewell WH,Koth DR,Huggins CE.Ventricular fibrillation in dogs after sudden return of flow to the cornary artery. Surgery. 1955;38(6):1050-1053
[18] Jennings RB,Sommers HM,Smyth GA,et al.Myocardial necrosis induced by temporary occlusion of a coronary artery in the dog.Arch Psthol.1960;7(70):68-78.
[19] 蓝旭,刘雪梅,葛宝丰,等.β-七叶皂贰钠抗肢体缺血-再灌注损伤的作用[J].中国微循环,2001,15(3):441-446.
[20] 陈建常,史振满,王乐农,等.丹参对缺血肢体关节软骨及滑膜损伤的影响[J].骨与关节损伤杂志,2000,15(2):121.
[21] 蓝旭,刘雪梅,葛宝丰,等.银杏叶提取液抗肢体缺血一再灌注损伤[J].中国骨伤,2002,15(8):471-472 .
[22] 李晖,姜凤元,郭龙.黄茂与维生素E对肢体缺血再一灌注损伤的保护作用[J].陕西医学杂志,2004,33(3):215-217.
[23] 李翠琴,黄仲海.补阳还五汤在中老年慢性病中的应用[J].求医问药:学术版,2011,9(6):421-425.
[24] 王晓霞,李荣亨.补阳还五汤作用机制研究进展[J].中西医结合心脑血管病杂志,2008,6(5):574-577.
[25] 李洁,纪爱娟,王莉莉.补阳还五汤治疗充血性心力衰竭临床观察[J].中西医结合心脑血管病杂志,2011,9(3):292-293.
[26] 吴常青,汪春彦,郡旭.补阳还五汤有效部位对大鼠局灶性脑缺血再灌注损伤保护作用及机制[J].中草药,2011,42(1): 114-117.
[27] 朱太咏,王健智.加味补阳还五汤注射液促进神经纤维体外生长的实验研究[J].中国中西医结合杂志,1995,15(S1):96-99.
[28] 赵梅青,季晓东.加味补阳还五汤治疗脑梗死疗效观察[J].中国中医急症,2012,21(8):578-579.
[29] Sasaki H,Matsuno T,Tanaka N,et al.Activation of apoptosis during the reperfusion phase after rat liver ischemia. Transplan Proc.1996;28(3):1908.
[30] Kuo PC,Drachenberg CI,dela Torre A,et al.Apoptosis and Hepatic allograft reperfusion injury.Clin Transplant.1998; 12(3):219.
[31] Borghi G,Scoazec JY,Durand F,et al.Apoptosis after ischemia reperfusion in human liver allograft.Liver Transpl Surg.1997; 3(4):407.
[32] Sasaki H,Matsuno T,Ishikawa T,et al.Activation of apoptosis during early phase of reperfusion after liver transplantation. Transplan Proc.1997;29(1):40.
[33] Park JL,Luchesi BR.Mechanisims of myocardial reperfusion injury.Ann Thorac Surg.1999;68:1905-1912.
[34] Carden DL,Granger DN.Pathophysiology of ischemia-reperfusion injury.J Pathol.2000;190:255.
[35] Wang LF,Zhang HY.A theoretical investigation on DPPH radical/ scavenging mechanism of edavone.Bioorg Med Chem Lett.2003;13 (21):3789.
[36] 宋煊赫,高丽萍,李志海,等.钙拮抗剂减轻大鼠皮瓣缺血一再灌注损伤的效应[J].中国临床康复,2006,10(4):78-79.
[37] Katare GR,Shiro S.Antioxidant MCI-186 inhibits mitochondrial perme- ability transition pore and up regulates BCL-2 expression. AJP Heart.2003;285:2171.
[38] Jaeschke H. Molecular mechanism of hepatic ischemiare-perfusion injury and Preconditioning.Am J Physiol Gastrointest liver Physiol.2003;284:G15-G26.
[39] Kato R,Foex P.Myocardial protect ion by anesthetic agents against ischemia - reperfusion injury : an update for anesthesio- logists.Can J Anaesth. 2002; 49(8): B777-791.
[40] Harkin DW,Dsa AA,Yassin MM,et al.Reperfusion injury is greater with delayed restoration of venous outflow in concurrent arterial and venous limb injury.Br J Surg.2002; 89(2):245.